Here's why a sugar-free diet reduces epileptic seizures

Editorial note: This article was previously published and has been updated according to scientific and divulgative criteria. It is for informational purposes only and does not replace medical advice.

IN BRIEF

• The ketogenic diet (high-fat, low-carb) is a recognized therapeutic option for some forms of drug-resistant epilepsy.
• Clinical evidence shows significant reductions in seizure frequency in many children and some adults; benefits vary by diagnosis, adherence, and treatment duration.
• Proposed mechanisms include the shift from glucose to ketone utilization, modulation of KATP channels, inhibition of glutamate transporters, and mitochondrial/antioxidant effects.
• A laboratory study linked the BAD protein to the regulation of brain metabolism and seizure resistance; this pathway provides hypotheses for alternative metabolic drugs.
• The evidence does not justify absolute claims: treatment choice must be personalized and supervised by specialists.

Abstract: what does science say?

The ketogenic diet is a dietary protocol with reduced carbohydrate intake and a high proportion of fats which, in many cases of drug-resistant epilepsy, reduces seizure frequency. Randomized clinical trials and pediatric guidelines document a detectable therapeutic effect within weeks-months; however, the magnitude of the response is variable and depends on diagnostic factors, adherence, and the specific type of diet. Mechanistically, the metabolic transition from glucose to ketones alters neuronal bioenergetics, reduces oxidative stress, and modifies synaptic transmission, with potential roles for KATP channels, glutamate transporters, and metabolic enzymes (e.g., LDH). Laboratory research has also associated the BAD protein with interference in brain metabolism and neuronal excitability, opening up possibilities for pharmacological targets.

MAIN SECTION

What is the ketogenic diet and when is it used?

The ketogenic diet (KD) consists of a very low carbohydrate intake, moderate protein, and high percentages of fats, aimed at inducing a metabolic state called ketosis. In the clinical setting, KD has historically been used for pediatric forms of drug-resistant epilepsy and, more recently, also adapted for adults through variants such as the medium-chain triglyceride (MCT) diet, the modified Atkins diet (MAD), or the low-glycemic index treatment (LGIT). A randomized trial in children with drug-resistant epilepsy documented a significant reduction in seizures in the first few months compared to the control group, consolidating KD's role as a therapeutic option in specialized centers [1]. International guidelines and recommendations provide clinical indications on patient selection, nutritional monitoring, and management of side effects [2].

How effective is the diet: what clinical studies show

The clinical literature includes controlled studies, case series, and reviews which, overall, indicate that a significant proportion of patients with refractory epilepsy reduce seizure frequency with KD; in some cases, seizure freedom is achieved for long periods. The variability of response is wide: some patients do not benefit, others partially reduce seizures, and a minority achieve remission. Results depend on the specific diagnosis, age, adherence to the diet, and dietary variants used [1][2].

Plausible biological mechanisms: what happens in the brain

Many mechanistic explanations have been proposed and often coexist. The shift from glucose to ketone utilization provides an alternative energy source (β-hydroxybutyrate, acetoacetate) that can improve mitochondrial function and reduce the production of reactive oxygen species, limiting vulnerability to excitotoxicity [6]. Ketones can also influence synaptic transmission: acetoacetate has been shown in experimental models to inhibit vesicular glutamate transporters, decreasing glutamate content in vesicles and thus synaptic excitation [5]. A further mechanism concerns ATP-sensitive channels (KATP): the reduction in glycolytic metabolism and the modification of local energy ratios can promote the opening of channels that hyperpolarize neurons and limit excitability, an effect supported by both experimental data and theoretical work on the metabolic regulation of excitability [4][3].

The role of the BAD protein: a bridge between metabolism and excitability

Laboratory research conducted in animal models has shown that modulation of the BAD protein (BCL-2-associated agonist of cell death) alters mitochondrial fuel preference in the brain and susceptibility to seizures. In particular, variants that reduce glucose utilization shift metabolism towards ketones and are associated with increased KATP channel activity and seizure resistance in experimental models. These results, obtained in studies conducted by groups including Nika N. Danial and Gary Yellen and colleagues, suggest that the molecular regulation of metabolism can reproduce aspects of the diet's effect, opening avenues for targeted pharmacological approaches [3].

Other metabolic and pharmacological targets

More recent studies have identified further possible targets: the regulation of lactate dehydrogenase (LDH) and the astrocyte-neuron lactate shuttle pathway has been proposed as a pharmacologically manipulable mechanism; LDH inhibition has produced anticonvulsant effects in experimental models, suggesting the possibility of non-dietary strategies that mimic the metabolic effect of KD [7]. Recent reviews collect and examine these mechanisms, emphasizing that there is probably not a single mechanism but a set of metabolic, synaptic, and inflammatory effects [8].

PRACTICAL SECTION

What it means in practice

For those living with epilepsy, the practical message is that the ketogenic diet can be an effective therapy, especially in cases where medications do not control seizures. Its application requires a specialized pathway: initial evaluation by experienced neurologists and dietitians, selection of the most suitable dietary variant, monitoring of side effects (nutritional deficiencies, metabolic alterations, growth changes in children), and continuous re-evaluation of efficacy. Therapeutic decisions must be shared and personalized, taking into account patient and family preferences and the practical feasibility of a restrictive diet [2].

Who can benefit and who cannot

KD is primarily indicated for drug-resistant epilepsies and certain specific epileptic syndromes. Not everyone responds, and predicting the response is currently imprecise: factors such as the cause of epilepsy, age of onset, genetic or metabolic profile, and the ability to maintain the diet influence efficacy [2][1]. Therefore, it is not advisable to adopt the diet independently without clinical supervision.

KEY POINTS TO REMEMBER

• The ketogenic diet is a therapy with clinical evidence for some drug-resistant epilepsies, but the response is variable and requires specialist follow-up. [1][2]
• Mechanisms include multiple pathways: mitochondrial energy changes, modulation of ion channels (e.g., KATP), inhibition of vesicular glutamate transporters, and antioxidant actions. [6][5][4]
• Laboratory studies have linked the BAD protein to the regulation of brain metabolism and seizure resistance, suggesting potential pharmacological targets that mimic KD. [3]
• Non-dietary approaches (e.g., LDH inhibitors) are in preclinical and experimental stages; clinical translation requires further research. [7]
• KD requires a multidisciplinary approach; it is not without nutritional and metabolic risks and does not replace pharmacological therapies without supervision. [2]

LIMITATIONS OF EVIDENCE

It is important to distinguish between types of studies: clinical studies include randomized trials, observational studies, and case series. Although there are trials supporting the efficacy of KD, the literature shows heterogeneity in dietary protocols, definitions of response, and patient selection criteria. Many proposed mechanisms derive from animal models or in vitro studies, which provide biological plausibility but do not demonstrate direct causality in humans. Furthermore, the measurement of plasma ketones does not always correlate linearly with seizure control, suggesting that other metabolic or synaptic factors contribute to the clinical benefit [8][6]. Among the methodological limitations: small sample sizes in many studies, limited follow-up to evaluate long-term effects, and difficulty in controlling confounding variables related to dietary adherence. For these reasons, clinical recommendations emphasize the need for personalized pathways and larger, more controlled future studies [2][8].

Editorial Conclusion

Current scientific knowledge confirms that manipulating brain metabolism—with the ketogenic diet or targeted pharmacological approaches—can reduce neuronal excitability and seizure frequency in many forms of refractory epilepsy. Laboratory research, including work linking the BAD protein to the regulation of metabolism and KATP channels, provides plausible mechanisms that partly explain the clinical effect. However, significant uncertainties remain, and translation into clinical practice requires specialized management, continuous monitoring, and long-term studies. The future role of metabolic therapy may expand with new drugs that reproduce parts of the diet's effect, but for now, KD remains a therapeutic tool to be evaluated on a case-by-case basis in competent clinical settings.

EDITORIAL NOTE

This article has been updated in light of international evidence and reviews. The information contained herein is for divulgative purposes and does not replace specialist medical consultation. For therapeutic decisions, consult a neurologist and dedicated nutritional team.

SCIENTIFIC RESEARCH

1. Neal EG, Chaffe H, Schwartz R, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008. https://doi.org/10.1016/S1474-4422(08)70092-9
2. Kossoff EH, Zupec‑Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018. https://doi.org/10.1002/epi4.12225
3. Giménez‑Cassina A, Martínez‑François JR, Fisher JK, et al. BAD‑dependent regulation of fuel metabolism and K(ATP) channel activity confers resistance to epileptic seizures. Neuron. 2012. https://doi.org/10.1016/j.neuron.2012.03.032
4. Lutas A, Yellen G. The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci. 2013. https://doi.org/10.1016/j.tins.2012.11.005
5. Juge N, Gray JA, Omote H, et al. Metabolic control of vesicular glutamate transport and release. Neuron. 2010. https://doi.org/10.1016/j.neuron.2010.09.002
6. Maalouf M, Sullivan PG, Davis L, Kim DY, Rho JM. Ketones inhibit mitochondrial production of reactive oxygen species following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience. 2007. https://doi.org/10.1016/j.neuroscience.2006.11.065
7. Sada N, Lee S, Katsu T, et al. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015. https://doi.org/10.1126/science.aaa1299
8. Simeone TA, Simeone KA, Stafstrom CE, Rho JM. Do ketone bodies mediate the anti‑seizure effects of the ketogenic diet? Neuropharmacology. 2018. https://doi.org/10.1016/j.neuropharm.2018.01.011

[If some bibliographic data or specific details were missing in the updated text, explicit placeholders have been left: [PLACEHOLDER].]